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Primary prevention of rheumatic fever 
in children: Key factors to consider 
To the Editor: We applaud the efforts by Irlam et al.[1,2] to conduct 
a cost-effectiveness analysis of primary prevention of rheumatic 
fever (RF) in children. The authors used a Markov decision analysis 
cohort model to assess seven different treatment strategies for 
children presenting with sore throat. A particular strength of the 
study was the inclusion of costs relating to secondary prevention and 
development of chronic rheumatic heart disease (RHD). The authors 
concluded that using clinical criteria for the diagnosis of pharyngitis 
without culturing for group A streptococci is the most cost-effective 
intervention for the prevention of RF and RHD in settings where 
these diseases are endemic.[1] However, we believe that they have not 
fully considered several important issues.
The authors chose to use a clinical decision rule to diagnose group 
A streptococcal pharyngitis in children presenting with sore throat 
that requires only two of three features to be present for treatment 
to be initiated: enlarged cervical nodes; absence of rash; and absence 
of rhinitis.[3] This clinical decision rule is highly sensitive (92%), but 
is poorly specific (38%), which means that while only 8/100 children 
would be missed, 62/100 children with sore throat would receive 
antibiotic treatment unnecessarily. While this strategy may be better 
than treating all, we believe that the authors have underappreciated 
the importance of the unintended consequences resulting from 
overuse of antibiotics, particularly antibiotic resistance. The authors 
correctly point out that resistance to penicillin in group A streptococci 
has never been reported; however, they did not consider the impact 
of widespread use of penicillin on drug resistance developing in 
other bacteria. A key example is the promotion of penicillin-resistant 
Streptococcus pneumoniae, a worldwide health problem that was 
originally described in South Africa (SA), where it is has been 
strongly associated with injudicious use of antibiotics in patients with 
viral infections.[4-6]
Some of the probability assumptions used in the model may not 
be applicable to most settings. A key issue in this study was the 
incidence of sore throat used (8.7/1  000 child years, 0.87%). This 
figure, derived from an RF registry in the Vanguard community, is 
extremely low compared with published data, which suggest that 
sore throat occurs in at least 33% of children/year.[7-9] The study 
used a figure of 15% for the prevalence of group A streptococci in 
the pharynx; this means that only 1 - 2 of every 1  000 children/
year experience a group A streptococcal sore throat (1.3/1 000 child 
years). Data from other RF-endemic countries suggest a far higher 
incidence of group A streptococcal sore throat by a factor of over 
100 times: 147/1  000  child years in Fiji and up to 950/1  000  child 
years in India.[9,10] The very low incidence of both sore throat and 
group A streptococcal-positive sore throat reported by Irlam et al. 
suggests that many SA children do not present for care, which is a 
concern for a public healthcare programme that relies on treatment 
of sore throat. In addition, the use of such a low incidence of group A 
streptococcal sore throat may have underestimated the expected costs 
from associated complications.
The study did not include rapid group A streptococcal antigen 
tests in the Markov model on the basis that these tests have ‘low 
sensitivity’. While the sensitivity of a few of these tests is low, the 
majority of modern tests have sensitivity >85% and nearly all have 
high specificity (>95%).[11] A number of immunoassay rapid tests 
and the majority of the newer molecular rapid tests have sensitivity 
>90%. These figures compare very favourably with the clinical 
decision rule outlined in the study, particularly because the higher 
specificity of rapid tests would substantially reduce overdiagnosis. 
Rapid tests have decreased in cost over time, with many being 
cheaper than culture, and potentially applicable to low-income 
settings. Rapid tests have clear advantages for the diagnosis of group 
A streptococcal pharyngitis because an on-the-spot clinical decision 
can be made. This is important because a considerable portion of the 
cost attributed to culture in the study by Irlam et al. was the cost of a 
return visit, which would be obviated by a rapid test. We believe that 
a low-cost rapid test that has high sensitivity and a fast turnaround 
time should be a research priority for the RF research community, 
particularly in low-income settings.
Diagnosis and treatment of group A streptococcal pharyngitis is 
important in the control of RF and RHD. We agree with the authors 
that in resource-poor populations, the very ones that are most 
affected by rheumatic disease, a pragmatic approach to the diagnosis 
of group A streptococcal pharyngitis that minimises cost is necessary. 
However, factors other than cost, such as antibiotic resistance and 
the likelihood of the target population presenting with sore throat, 
should also be considered when developing clinical guidelines and 
public health interventions. 
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Irlam et al. respond: We appreciate the interest of Steer and Danchin 
in our article,[1] and wish to respond to the key issues they raise. 
Their concern about the overuse of penicillin on the resistance of 
bacteria other than group A streptococci is certainly a valid one that 
requires close attention. SA has had one of the highest reported rates of 
pneumococcal penicillin resistance in the world,[2] but the full impact 
of resistance in S. pneumoniae in our setting needs to be properly 
assessed.[3] While overuse of penicillin for the treatment of suspected 
group A streptococcal pharyngitis may affect pneumococcal resistance 
rates, this needs to be weighed against the risk of a missed streptococcal 
throat progressing to acute rheumatic fever (ARF).
The very low incidence of sore throat (8.7/1 000 child years) and 
prevalence of group A streptococcal-positive sore throat (15% in 
children presenting with sore throat, 0.13% overall) in the Vanguard 
Study Area population between June 2008 and June 2010 may largely 
be a result of under-presentation at urban primary healthcare clinics 
in this setting. Incidence data for this study were derived from all 
the clinics covering a defined local geographical area of Cape Town. 
While patients attending private medical facilities would have been 
missed, it is expected that this will be a very small number, because 
most people in the area use public sector healthcare facilities. As we 
showed in our original paper, however, the higher the incidence, 
the more cost-effective either the clinical decision rule or ‘Treat All’ 
strategies become, which makes our results even more applicable to 
regions with higher incidence.[4] When we used rates similar to those 
suggested by Steer and Danchin, the strategy of ‘Treat All’ becomes 
preferable. Nevertheless, in our paper we call for wider efforts to 
complement this opportunistic, cost-effective, passive strategy of 
RF and RHD prevention at primary healthcare clinics. For example, 
active screening for RHD using portable echocardiography and 
computer-assisted auscultation followed by secondary prophylaxis 
is currently being undertaken and evaluated in schools in the same 
community.[5]
Our primary reason for the exclusion of rapid group A streptococcal 
antigen tests in the Markov model was that these tests are not currently 
used in public sector primary healthcare settings in SA. We agree that 
a low-cost rapid test with high sensitivity and a fast turnaround time 
should be a research priority that may, in the light of cost-effectiveness 
modelling and large-scale evaluation studies, prove to be a very useful 
addition to updated clinical guidelines for the management of RF and 
RHD in the public sector in SA. Funding is currently being sought to 
conduct a study on the utility of rapid streptococcal tests.
We thank Steer and Danchin for their critique. We share their 
concern for safety and effectiveness as well as cost in developing clinical 
guidelines and public healthcare interventions for early prevention of 
ARF and RHD.
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